Hutchmed (china) vs Mirum Pharmaceuticals
Hutchmed (china) and Mirum Pharmaceuticals are similar in size: $549m and $521m of revenue in their latest fiscal years. Mirum Pharmaceuticals grew faster (54.7% against -13.0%). Hutchmed (china) kept more of each dollar of sales as profit: a net margin of 83.3% against -4.5%. Hutchmed (china) carries less debt relative to equity (9.5% against 98.4%).
| Latest fiscal year | Hutchmed (china)HCM, 2025 | Mirum PharmaceuticalsMIRM, 2025 |
|---|---|---|
| Revenue | $549m | $521m |
| Revenue growth | -13.0% | 54.7% |
| Net income | $457m | −$23.4m |
| Operating margin | -7.1% | -4.2% |
| Net margin | 83.3% | -4.5% |
| Return on equity | 45.7% | -8.6% |
| Free cash flow | −$78.8m | $54.9m |
| Cash | $71.3m | $297m |
| Total debt | $118m | $310m |
| Debt to equity | 9.5% | 98.4% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | 372 |
| Market value | $2.29bn | $5.61bn |
| Price vs our value range | Above our value range | — |
| Moat score | — | 10 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 1 buys, 59 sales |